Romani & Puccetti reply

L. Romani and P. Puccetti ()
Additional contact information
L. Romani: University of Perugia, 06132 Perugia, Italy
P. Puccetti: University of Perugia, 06132 Perugia, Italy

Nature, 2014, vol. 514, issue 7523, E18-E18

Abstract: Abstract Replying to G. J. Maghzal et al. Nature 514, 10.1038/nature13844 (2014) After our initial observation of defective tryptophan catabolism in experimental chronic granulomatous disease (CGD)1, several laboratories have been testing the indoleamine 2,3-dioxygenase (IDO1) competence of cells from CGD patients. In most instances, they found no impairment in IDO1 competence in terms of tryptophan catabolic activity in vitro by polymorphonuclear leukocytes and monocyte-derived dendritic cells2,3, leading to the conclusion that there is no obvious defect in the production of kynurenine (the first by-product of tryptophan degradation)—hence in the IDO1-dependent mechanism of tolerogenesis as a whole in human CGD. In the accompanying Comment4, Maghzal et al. report that tryptophan catabolism is unaffected in chronic granulomatous disease, again by measurements of kynurenine production.

Date: 2014
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature13845 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:514:y:2014:i:7523:d:10.1038_nature13845

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature13845

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().